European Medicines Agency (EMA) Incentives for Orphan Drugs
European Medicines Agency (EMA) Incentives for Orphan Drugs Unlocking EMA Incentives for Orphan Drug Development in the European Union Understanding Orphan Designation in the European Regulatory Context Orphan drug development in the European Union (EU) is governed by Regulation (EC) No 141/2000, which was implemented in 2000 to stimulate investment into therapies for rare conditions….
Read More “European Medicines Agency (EMA) Incentives for Orphan Drugs” »